Pakistan man is first foreigner to receive umbilical cord blood

SHANGHAI: A patient from Pakistan has become the first foreigner to receive umbilical cord blood in China as part of a hematopoietic stem cell transplant to restore his ability to produce his own healthy blood cells.

Tahseen Dilbar received an umbilical cord blood transfusion from Shanghai Cord Blood Bank under China Stem Cell Group, the only licensed umbilical cord blood bank in the city.

More than 3,200 Chinese people received the treatment ahead of him.

The 30yearold Dilbar is recovering at Shanghai General Hospital, where he received the transplant on Wednesday and Thursday.

Umbilical cord blood was injected into his body along with halfmatched stem cells donated by his elder brother.

“Halfmatched hematopoietic stem cell transplants usually invite strong rejection from the recipient’s body,” said Wang Chun, director of the hospital’s hematology department.

“The addition of matched umbilical cord blood can effectively reduce the chance of rejection.”

Dilbar is expected to regain his ability to produce healthy blood cells in two weeks and fully recover in around two months, he added.

Dilbar was diagnosed in 2010 with myelodysplastic syndrome (MDS), a group of disorders characterised by bone marrow’s inability to grow enough healthy blood cells.

Over the past eight years, he had relied on blood transfusions to survive, but his condition worsened.

By the end of last year, he was at high risk of developing acute myeloid leukemia (AML), which usually features the rapid growth of abnormal cells that build up in the bone marrow and blood, and interfere with normal blood cells. As acute leukemia, AML progresses rapidly and is typically fatal within weeks or months if left untreated.

Stem cell transplantation is regarded as the most effective treatment for MDS. But Dilbar failed to find a full match among his three brothers and sisters. One elder brother’s hematopoietic stem cells showed only a halfmatch, according to Dilbar’s wife, Jasmin Tahira.

While Pakistan performs transplants with wholly matched hematopoietic stem cells, it is not up to handling halfmatched ones, she said.

Doctors in Pakistan suggested treatment in China, where Wang and his team are known as pioneers in the transplant of halfmatched hematopoietic stem cells.

The addition of matched umbilical cord blood is an essential part of such transplants, Wang said.

Upon Dilbar’s arrival at the hospital in March, Wang applied for a match with the China Marrow Donor Programme and seven umbilical cord blood hematopoietic stem cell banks nationwide.

He later heard from the Shanghai branch that a match had been found.